[Skip to Navigation]
Editorial
March 4, 2020

Oral and Topical Terbinafine for Fungal Infections in Pregnancy

Author Affiliations
  • 1Department of Dermatology, University of California, San Francisco
  • 2University of California School of Medicine, San Francisco
  • 3Department of Dermatology, Palo Alto Foundation Medical Group, Mountain View, California
JAMA Dermatol. 2020;156(4):371-372. doi:10.1001/jamadermatol.2019.5036

Dermatologists face difficult questions about the safety of topical and systemic medications during pregnancy and lactation. Safety data regarding these medications can be limited to case studies, animal models, or small cohort studies that lack statistical power. Given the ethical complexities of pregnancy, randomized clinical trials evaluating the use of potentially teratogenic medications are often unfeasible; thus, large cohort studies are typically needed to inform practice.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×